- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07439185
A tücsök és fekete katonalégy-lárvával dúsított keksz hatása a malgas iskolások bélmikrobiomájára és vasállapotára
A tücsök és fekete katonalégy-lárvával dúsított keksz hatása a bélmikrobiomra és a vasállapotra madagaszkári iskolásoknál
The purpose of this study is to determine the health impacts of consistent consumption of insect-fortified crackers among school-aged children in Madagascar.
Specifically, in this RCT, the investigators will assess whether the insect-fortified crackers can improve the health status of Malagasy school children. The investigators' objectives are to: (1) Assess changes in gut microbiome composition that occur after 6 and 14 weeks of cracker consumption through 16S rRNA sequencing. (2) Assess changes in intestinal and systemic inflammation after 6 and 14 weeks of cracker consumption through quantification of fecal calprotectin, lactoferrin, myeloperoxidase (MPO), and alpha-1-antitrypsin (AAT) and circulating pro-inflammatory cytokines. (3) Assess changes in iron status after 14 weeks of cracker consumption through quantification of hemoglobin (Hb), inflammation-adjusted serum ferritin, and soluble transferrin receptor (sTfR).
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
Food insecurity, child malnutrition, and anemia remain significant public health problems globally, including in Madagascar where 40% of children under 5 years of age are chronically malnourished (stunted), 8% are wasted, and 46% are anemic (DHS, 2021). Interventions aimed at addressing this have often foundered on the fact that the foods that would address these nutrient deficiencies are physically unavailable, too expensive for poor households to purchase, or contribute to climate change or environmental degradation. Consequently, there is interest in the development of novel food products that could contribute to reducing malnutrition in all its forms, without the drawbacks of relying on existing food products. One possibility is to develop food products based on insects. Edible insects are low-cost, climate friendly, with nutritional profiles akin to meat. They contain high amounts of protein, iron, and zinc while also providing a novel source of prebiotic fiber. It is hypothesized that insect-based foods could improve children's health outcomes as measured by gut inflammation, anemia, and growth. The investigators and others have developed an insect-fortified cracker snack, suitable for the nutritional requirements of school-age children living in Southeast Madagascar. The investigators have already assessed the product's nutrient profile. They also have documented the safety tests done to date; these show that the snack is safe for human consumption. The test results have been submitted to the Malagasy regulatory authority for registering food and health products and the government has approved the insect powders as food for human consumption and issued "Certificates for Human Consumption". The investigators have also conducted an acceptability trial that showed that child participants like the organoleptic characteristics of the crackers and regularly consume the crackers in biologically meaningful quantities.
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Vakinankaratra Region
-
Antsirabe, Vakinankaratra Region, Madagaszkár
- FSRP Sschools
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion criteria for children
- Child (male, female, intersex, non-binary), aged 9 to 13 years old who attends one of the selected schools
- Caregiver or legal guardian is willing to provide informed consent
- Child is willing to provide informed assent
Exclusion criteria for children
- Child age is outside the preferred age range (9 to 13 years)
- Not enrolled in the participating schools
- Unable or unwilling to comply with the study requirements
- Illness requiring medical treatment, malaria, severe anemia (hemoglobin (Hb) concentration below 8.0 g/dL as indicated by HemoCue 201+ system), severe acute malnutrition, fever, diarrhea, etc.
- Covid-exposure or symptoms: loss of smell or taste
- History of food allergies or adverse reactions to any edible insects
- Chronic severe medical condition or congenital anomalies requiring frequent medical attention or interfering with dietary consumption
- Caregiver does not give consent, or child does not assent
Inclusion criteria for parents • Willing to participate in completing surveys about demographics and household dynamics (assets, housing structure, etc.)
Exclusion criteria for parents
• Caregiver does not consent to participate
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Alapvető tudomány
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Hármas
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Treatment
Consumption of insect-fortified (crickets and black soldier fly larvae) crackers. |
Children will receive a sachet containing 50g of insect crackers. 50 grams was chosen as the amount because the investigators know, from their earlier acceptability trial, that children are willing to consume this amount (in the acceptability trial, approximately 80% of children consumed 80% or more of the 50g of crackers that they were provided). Crackers will be provided Monday-Friday for approximately 14 weeks.
Más nevek:
|
|
Placebo Comparator: Control
Consumption of rice and corn crackers |
Children will receive a sachet containing 50g of insect crackers. 50 grams was chosen as the amount because the investigators know, from their earlier acceptability trial, that children are willing to consume this amount (in the acceptability trial, approximately 80% of children consumed 80% or more of the 50g of crackers that they were provided). Crackers will be provided Monday-Friday for approximately 14 weeks.
Más nevek:
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Gut mircrobiome
Időkeret: From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess gut microbiome composition at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through 16S rRNA sequencing and quantification of fecal biomarkers. |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Iron via soluble transferrin receptor
Időkeret: From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through soluble transferrin receptor (mg/L). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Intestinal inflammation via calprotectin
Időkeret: From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: calprotectin (µg/g). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Intestinal inflammation via lactoferrin
Időkeret: From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: lactoferrin (µg/g). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Intestinal inflammation via lipocalin
Időkeret: From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: lipocalin (ng/g). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Intestinal inflammation via anlpha-1 antitrypsin
Időkeret: From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: anlpha-1 antitrypsin (mg/g). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Intestinal inflammation via myeloperoxidase
Időkeret: From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: myeloperoxidase (µg/g). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Systemic inflammation via quantification of circulating cytokines
Időkeret: From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will also assess systemic inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through quantification of circulating cytokines, including IL-1β, IL-2, IL-4, IL-6, IL-10, IL-22, TNF-α, IFN-γ, CCL2, all expressed as pg/mL. |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Iron via quantification of hemoglobin
Időkeret: From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through quantification of hemoglobin (g/dL). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Iron via inflammation adjusted ferritin
Időkeret: From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through inflammation adjusted ferritin (µg/L). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Tanulmányi szék: John Hoddinott, DPhil, Cornell University
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Egyéb vizsgálati azonosító számok
- IRB0149913
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD megosztási időkeret
July 2026 to July 2027
Az IPD megosztását támogató információ típusa
- STUDY_PROTOCOL
- NEDV
- ICF
- ANALYTIC_CODE
- CSR
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
az Egyesült Államokban gyártott és onnan exportált termék
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .